Global Antithrombin Market: Industry Analysis and Forecast (2020-2026)

[mayuri kathade]

Global Antithrombin Marketis expected to reach $XX Mn by 2026 from $XX Mn in 2019, at a CAGR of 4.5% during forecast period.
Global Antithrombin Market Overview:

Antithrombin (AT) is a small protein molecule that aids in the inactivation of coagulation system enzymes. It's often used during surgical procedures in patients with low antithrombic levels, and it serves as a natural blood thinner. Antithrombin is a serine protease inhibitor with a structure similar to alpha 1-antichymotrypsin, alpha 2-antiplasmin, and heparin cofactor II.

Global Antithrombin Market Dynamics:

Rising prevalence of surgical procedures and advances in the technology are the major drivers for the market growth.

Antithrombin is being used to treat many medical conditions such as sepsis, hereditary antithrombin deficiency, disseminated intravascular coagulation (DIC), and extracorporeal membrane oxygenation (ECMO). Increasing incidences of these conditions are creating potential growth opportunities for the Antithrombin market. According to the Centres for Disease Control and Prevention (CDC), venous thromboembolism affects about 900,000 people in the United States each year. Furthermore, hereditary thrombophilia puts 5 to 8% of the population in the United States at risk of thrombosis due to one of many genetic risk factors. Clopidogrel, a currently approved antiplatelet agent, meets some of these requirements and has contributed significantly to the antithrombotic market's recent development. Furthermore, the use of antithrombin and heparin may be more effective in the treatment of patients with antithrombin disorders. Antithrombin benefits and applications contribute to the market's development. The rising number of surgeries conducted worldwide and the risk of excessive bleeding during these procedures is expected to boost the market growth. Along with this, Therapeutic drug advances are also expected to drive market growth. Fitusiran (ALN-AT3), a subcutaneously administered investigational RNAi therapeutic targeting antithrombin, was developed by Alnylam Pharmaceuticals, Inc. (AT). This therapeutic, which can be used to treat hemophilia and rare bleeding disorders (RBDs), is currently in a late-stage clinical trial (Phase 2-phase 3).

However, the high cost for antithrombin procedure and lack of adequate technological infrastructure in underdeveloped economies are expected to restrain the market growth. In addition to this, increased use of biologics and availability of alternative options may also impact negatively on the market growth.

The report has profiled seventeen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.
Global Antithrombin Market Segment Analysis:

The global Antithrombin market is segmented on the basis of Application, Source and Dosage form.

Based on the Application, the Therapeutics segment is anticipated to hold the largest market share over the forecast period. It accounted for a market share of 95% in the year 2019. It has widespread application in the therapeutics area. Antithrombin can be used to treat conditions such as heart surgery and genetic disorders such as Antithrombin Deficiency. According to data released by the American Society of Haematology, 900,000 people in the United States produce blood clots per year, resulting in nearly 100,000 deaths. According to the National Organization for Rare Disorders, Type I antithrombin deficiency affects one in every 3000 to 5000 individuals in the United States.

Antithrombin is being used both therapeutically and diagnostically as the incidence of blood clotting disorders rises.
Based on Dosage Form, the Lyophilized segment held the largest market share in 2019. The lyophilized dosage type is commonly available and has a long expiration date. It also contributes to the growth of this segment by maximizing the integrity and ease of processing a liquid.

Global Antithrombin market

To know about the Research Methodology :- Request Free Sample Report
Global Antithrombin Market Regional Insights:

Global Antithrombin market 1
North America is anticipated to account for dominant market share during forecast period.

The U.S. accounted for US$143.3 Million in the year 2020. This is due to a rise in antithrombin awareness, acceptance, and adoption in this region's countries. The popularity of antithrombin is growing in this area due to an increase in the number of people with coagulation disorders.
Asia Pacific is expected to witness lucrative growth during forecast years.

Asia Pacific Antithrombin Market is expected to expand at the fastest pace. The Antithrombin Market was worth US$ 179.7 million in the Asia Pacific alone in 2018. One of the main reasons for this increase is that developing countries like India and China are introducing new treatment procedures and techniques to combat different diseases.

The report also helps in understanding Global Antithrombin Market dynamics, structure by analyzing the market segments and project the Global Antithrombin Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Antithrombin Market make the report investor’s guide.
Global Antithrombin Market, Key developments:

Three major corporations dominated the global Antithrombin Market: SCL Behring, Grifols, and Shire. These three firms accounted for the largest market share among others in 2018. They have the most widely used anticoagulants dependent on human antithrombin. Apart from this, they have a wide distribution network that allows them to capture the largest market share.
Global Antithrombin Market Scope:
Inquire before buying

Global Antithrombin market 2
Global Antithrombin Market, By Region:

• North America
• Europe
• South America
• MEA
• APAC
Global Antithrombin Market, Key players:

• rEVO Biologics, Inc.
• Grifols
• CSL Limited
• Kedrion S.p.A
• Octapharma AG
• Dem ilac Inc.
• Lee Bisolutions
• Diapharma
• Scripps Laboratories, Inc.
• LFB USA
• Shire Plc.
• Takeda Pharmaceutical Company Limited
• Koliber Biosciences
• Siemens Healthcare Private Limited
• Aniara Diagnostica
• Sysmex Corporation
• Trinity Biotech PLC

For More Information Visit @:https://www.maximizemarketresearch.com/market-report/global-antithr...

            

 This Report Is Submitted By : Maximize Market Research Company

Customization of the report:          

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research: 

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.